

Program

14th Cancer Crosslinks 2022

Thursday, January 27, 2022– presented as a Live Produced Digital Meeting / complemented by Roundtables and networking opportunities (tbd based on COVID-19 related restrictions in Jan 2022)

Getting ahead of tumor evolution – changing the premises in the war against cancer	
11:45 – 12:00	Registration on-site & Log-in for live-stream
12:00 - 12:10	Opening and Welcome
	Moderators: Kristina Lindemann , Head of Research, Dept. of Gynecological Oncology, Oslo University Hospital and Åsmund Flobak , St. Olavs Hospital, Trondheim University Hospital
12:10 - 12:50	Tracking lung cancer evolution from early to late-stage disease – its clinical and therapeutic implications Mariam Jamal-Hanjani , Group Leader, Cancer Metastasis Lab, CRUK Lung Cancer Centre of Excellence, UCL Cancer Institute; Senior Clinical Lecturer and Honorary Consultant in Translational Lung Oncology, UCL Hospital, London, UK
12:50 - 13:30	Current and future methods of predicting response to Immunotherapy David Rimm , Anthony N. Brady Professor of Pathology, Professor of Medicine (Oncology), Director, Translational Pathology and Director, Yale Pathology Tissue Services; Director, Physician Scientist Training Program in Pathology, Yale University School of Medicine, New Haven, USA
13:30 - 13:50	COFFEE BREAK
13:50 - 14:20	Immunotherapy trials in the perioperative setting – Opportunity for clinical proof-of-concept and mechanistic exploration Martin Schuler , Professor, Director Department of Medical Oncology, University Hospital Essen; Spokesman for the German Cancer Consortium (DKTK), Partner Site University Hospital Essen, Germany
14:20– 14:50	Precision therapy for Gynecological Cancers with focus on Endometrial (Uterine) Cancer: molecular subtypes and emerging treatment options Angela George : Clinical Director of Genomics and Consultant Medical Oncologist in Gynecology, Royal Marsden, London, UK
14:50 - 15:10	COFFEE BREAK
	Moderator: Tobias Schmidt Slørdahl , St. Olavs Hospital, Trondheim University Hospital
15:10 – 15:40	Advances in Multiple Myeloma Treatment Using Proteasome Inhibitors (The proteasome and proteasome inhibitors: from biology to clinical impact) Christoph Driessen , Professor, Head of Clinical Trial Unit, Department of Oncology and Hematology, Kantonsspital St Gallen, St Gallen, Switzerland
15:40– 16:10	Gut microbiome in the immunotherapy arena: from biomarker to therapeutics Bertrand Routy , Assistant Professor of Hemato-Oncology, Centre de recherche - Centre hospitalier de l'Université de Montréal (CRCHUM), Montreal, Canada
16:10 – 16:15	Closing
From 16:15	On-site Networking Session (details tbd based on COVID-related restrictions in Jan)